Not a typo, just lack of attention to detail. They changed the...

Not a typo, just lack of attention to detail. They changed the Estimated Enrollment from 14 to 11 and then, realizing their mistake, changed it back again - probably after reading about this change on HC. They have made changes to the trial info on the 13th, 17th and 18th of this month.

As J8 said, at least we know that Claudia is still with us - even if she was left off the list of VP's. (More attention to detail?)

My guess is that, because dosing is weight dependent, there was insufficient TT-034 after above average weight patients were treated in the initial cohorts. This problem has now been rectified.

I agree with Umi, the news would be hard to understand in any context other than TT-034 proving to be successful. I also agree with Max that, in the context of recent announcements, this latest one is a little perplexing. At least it moved the share price in the right direction.